Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 4.97K
+4.61%+4.50%+33.77%+24.39% 227B
+3.01%+0.82%+10.16%-17.41% 143B
-0.21%+2.85%-16.13%+24.17% 134B
-2.62%-8.22%-57.29%-17.10% 65.29B
-0.31%+0.65%-18.37%-14.19% 50.09B
+0.26%-4.63%+10.53%+15.83% 49.29B
+2.36%-0.39%+21.93%+30.81% 41.39B
+1.73%+1.88%+41.20%+53.34% 40.28B
+2.89%+0.48%-15.07%+55.41% 31.9B
Average +1.48%-1.73%+1.19%+17.25% 86.84B
Weighted average by Cap. +2.22%-0.91%+6.28%+13.33%
Logo SpectraScience, Inc.
SpectraScience, Inc. is focused on developing its WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The Company has developed a technology platform to determine if tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT4 Optical Biopsy System operates by using cool, safe ultraviolet (UV) laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin immediate treatment during the same procedure. The WavSTAT4 uses laser-induced auto-fluorescence to obtain spectral information from tissue at the suspected site. The system is classified as a non-significant risk device, which transmits low-level UV laser light energy through an optical fiber to the tissue through the working channel of an endoscope.
Employees
7
  1. Stock Market
  2. Stocks
  3. SCIE Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!